芪参还五胶囊治疗帕金森病45例疗效观察  

Clinical effect of Qishen Huanwu capsule on 45 cases of Parkinson's disease

作　　者：袁春晓[1] 刘晓龙 段洪波[1] 马培锋[1] 郑建彪[1] YUAN Chunxiao;LIU Xiaolong;DUAN Hongbo;MA Peifeng;ZHENG Jianbiao(Department of Neurology,Cangzhou Hospital of Integrated Traditional and Western Medicine,Cangzhou,Hebei 061000,China)

机构地区：[1]河北省沧州中西医结合医院神经内科,河北沧州061000

出　　处：《安徽医药》2023年第10期2099-2102,共4页Anhui Medical and Pharmaceutical Journal

基　　金：河北省中医药管理局资助项目(2021295)。

摘　　要：目的探讨芪参还五胶囊对帕金森病病人的治疗效果。方法选取2019年8月至2021年8月河北省沧州中西医结合医院接收的90例帕金森病病人,采用随机数字表法随机分为中西医结合组(45例)和西药组(45例),西药组给予多巴丝肼治疗,中西医结合组给予芪参还五胶囊联合多巴丝肼治疗,比较两组病人中医证候积分、统一帕金森病评分量表(unified Parkinson’s disease rating scale,UPDRS)评分、血清胱抑素-C(Cystatin C,Cysc)、同型半胱氨酸(homocysteine,Hcy)、神经营养因子-3(neurotrophin-3,NT-3)水平、氧化应激指标-丙二醛(malonaldehyde,MDA)、超氧化物歧化酶(superoxide dismutase,SOD)、8-羟基脱氧尿苷酸(8-hydroxydeoxyguanosine,8-OHdG)水平,霍恩-雅尔(Hoehn-Yahr)分级评估病人肢体功能。结果中西医结合组病人各项中医证候积分[步态摇曳(0.38±0.11比0.22±0.06)、肢体震颤(0.33±0.09比0.16±0.05)、言语謇涩(0.49±0.13比0.36±0.10)、肢体拘挛(0.42±0.13比0.22±0.07)、便秘(0.63±0.18比0.29±0.08)]、UPDRS评分(11.46±3.72比5.25±1.69)分及血清Cysc(0.14±0.04比0.05±0.01)、Hcy(9.34±2.39比4.26±1.10)、NT-3(15.40±3.93比6.06±1.54)、MDA(5.33±1.36比2.87±0.75)、SOD(27.47±6.90比11.25±2.89)kU/L、8-OHdG(14.67±3.71比8.31±2.12)水平治疗前后差值均较西药组大(P<0.05);治疗后,中西医结合组病人Hoehn-Yahr分级为Ⅰ级、Ⅱ级人数明显多于西药组,Ⅲ级、Ⅳ级、Ⅴ级人数明显少于西药组(P<0.05)。结论芪参还五胶囊联合多巴丝肼用于帕金森病病人,能够改善病人中医证候及肢体运动功能,促进神经系统修复及降低病人氧化应激损伤水平,效果较好。Objective To investigate the therapeutic effect of Qishen Huanwu capsule on Parkinson's disease.Methods Ninety patients with Parkinson's disease admitted to Cangzhou Hospital of Integrated Traditional and Western Medicine in Hebei Province from August 2019 to August 2021 were randomly selected and randomly assigned into integrated traditional chinese and western medicine group(45 cases)and western medicine group(45 cases)using a random number table.The western medicine group was treated with dopaserizide,while the integrated traditional chinese and western medicine group was treated with Qishen Huanwu capsules combined with dopaserizide treatment.The TCM syndrome scores,unified Parkinson's disease rating scale(UPDRS)score,serum Cystatin C(Cysc),homocysteine(Hcy),neurotrophin-3(NT-3)level,oxidative stress indicators-malonaldehyde(MDA),superoxide dismutase(SOD),and 8-hydroxydeoxyguanosine(8-OHdG)]levels were compared among patients in the two groups,and the limb function of patients was evaluated by Hoehn-Yahr classification.Results The differences of TCM syndrome scores[Gait swaying(0.38±0.11 vs.0.22±0.06),limb tremors(0.33±0.09 vs.0.16±0.05),awkward speech(0.49±0.13 vs.0.36±0.10),limb cramps(0.42±0.13 vs.0.22±0.07),constipation(0.63±0.18 vs.0.29±0.08)],UPDRS scores(11.46±3.72 vs.5.25±1.69)and serum Cysc(0.14±0.04 vs.0.05±0.01),Hcy(9.34±2.39 vs.4.26±1.10),NT-3(15.40±3.93 vs.6.06±1.54),MDA(5.33±1.36 vs.2.87±0.75),SOD(27.47±6.90 vs.11.25±2.89)kU/L and 8-OHdG(14.67±3.71 vs.8.31±2.12)levels in integrated chinese and western medicine group before and after treatment were larger than those in western medicine group(P<0.05);after treatment,the numbers of patients with Hoehn-Yahr grade I andⅡin the integrated traditional chinese and western medicine group were significantly higher than those of the western medicine group,and the numbers of patients in gradeⅢ,Ⅳ,andⅤwere significantly less than those of the western medicine group(P<0.05).Conclusion Qishen Huanwu capsule combined with dopasraz

关 键 词：帕金森病 芪参还五胶囊 多巴丝肼 中医症候积分 胱抑素-C 

分 类 号：R742.5[医药卫生—神经病学与精神病学]